Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
16.52
+0.83 (5.29%)
Jul 9, 2025, 9:49 AM - Market open
Telix Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts that cover Telix Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $22.33, which forecasts a 35.17% increase in the stock price over the next year. The lowest target is $22 and the highest is $23.
Price Target: $22.33 (+35.17%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Telix Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +39.23% | Jul 3, 2025 |
| Wedbush | Wedbush | Buy Reiterates $22 | Buy | Reiterates | $22 | +33.17% | Jun 12, 2025 |
| Wedbush | Wedbush | Buy Initiates $22 | Buy | Initiates | $22 | +33.17% | Jun 5, 2025 |
| UBS | UBS | Strong Buy Maintains $21 → $22 | Strong Buy | Maintains | $21 → $22 | +33.17% | Jan 27, 2025 |
| UBS | UBS | Strong Buy Initiates $21 | Strong Buy | Initiates | $21 | +27.12% | Nov 15, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.